Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Bacteraemia Treated with Tigecycline Monotherapy-Validation of 2019's EUCAST Proposed Breakpoint Changes
Background: Tigecycline is a therapeutic option for carbapenemase-producing <i>Klebsiella pneumoniae</i> (CP-Kp). Our aim was to evaluate the impact of the tigecycline's minimum inhibitory concentration (MIC) in the outcome of patients with CP-Kp bacteraemia treated with tigecycline...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2020-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|